



Modelling Familial Hypercholesterolemia (FH) through CRISPR-derived LDLR pixHep

Familial hypercholesterolemia (FH) is a common inherited genetic disease with an estimated prevalence of 1 in 250 individuals. It is caused by pathogenic variants regulating the low-density lipoprotein (LDL) cholesterol plasma levels, with the majority of them identified at the low-density lipoprotein receptor (LDLR) genomic locus. Elevated LDL cholesterol accumulates in tissues, often leading to atherosclerosis and cardiovascular disease from a young age. Although certain drugs (e.g., statins, bile acid sequestrants) and lifestyle modification can alleviate some of the FH symptoms, a significant number of patients still cannot achieve optimal LDL levels. At pixlbio we have developed a novel iPSC derived hepatocyte system that recapitulates the human FH phenotype in-adish, offering an effective pre-clinical disease model for the large-scale screening of novel FH-related therapies.


Advantages

Functional cholesterol transport pathways with high expression levels of LDLR
Disease circuit verified carrying the E101K mutation in the LDLR gene
Optimized ApoB secretion assays as key endpoint in pixHep
Suitable in vitro platform for screening of compound and gene therapy systems
Standardized cell products containing iPSC-derived human hepatocytes producing reproducible and biologically relevant data



CASE STUDY

pixIbio CRISPR-derived LDLR iPSCs carry the E101K mutation without any effect in pluripotency status









Figure 1. Sanger sequencing showing wild-type (top sequence) and mutated iPSCs (bottom sequence) in two clones carrying the E101K mutation (GAG>AAG) in the LDLR gene (homozygous). The codon change is highlighted with yellow (left). mRNA expression levels of the key pluripotency markers NANOG, SOX2, and OCT4 in wild-type (WT) and two homozygous CRISPR-derived LDLR iPSC clones. mRNA data were normalized to GAPDH and are presented as mean±SEM of n=2 technical replicates (right).

pixIbio CRISPR-derived LDLR iPSCs successfully differentiate to pixHep












Figure 2. Representative images demonstrating the characteristic hepatocyte cobblestone morphology in wild-type (WT) and 2 LDLR-mutated pixHep clones (upper). mRNA expression levels of the hepatocyte maturity markers albumin (ALB), alpha-1-antitrypsin (A1AT), and hepatocyte nuclear factor 4A (HNF4A) in wild-type (WT) and 2 LDLR-mutated pixHep clones. mRNA data were normalized to PPIA and are presented as mean±SEM of n=3 biological replicates (lower).



CASE STUDY

pixIbio CRISPR-derived LDLR pixHep demonstrate increased ApoB secretion levels without any difference in LDLR expression








Figure 3. ApoB secretion in wild-type pixHep and 2 LDLR-mutated pixHep clones following 48 hours of treatment with lipidfree pixHep media (left). mRNA expression levels of LDLR gene in wild-type pixHep, 2 LDLR-mutated pixHep clones, and primary human hepatocytes (PHH) (middle). C) Protein expression levels of LDLR in wild-type pixHep, 2 LDLR-mutated pixHep clones, and PHH. Data are presented as mean±SEM of n=2 independent experiments. mRNA expression data were normalized to housekeeping gene PPIA. ApoB secretion data were normalized to total protein.